Expectedly, Akt inhibitor abrogated the ability of Gankyrin to activate GSK-3β/β-catenin signal, indicating that Gankyrin regulates GSK-3β/β-catenin signaling activation via a PI3K/Akt dependent mechanism in CRC. The gene discussed is GSK3B; the disease is colorectal carcinoma.